Amgen, Inc. (AMGN) Posts Solid Q3 Results; Boosts Buyback to $10B; Raises FY11 EPS Guidance
Tweet
Share
E-mailGet Alerts AMGN Hot Sheet
Price: $437.23 -1.55%
Revenue Growth %: +5.1%
Financial Fact:
Interest and other income, net: 216M
Today's EPS Names:
VIVO, BIOX, PMCB, More
Revenue Growth %: +5.1%
Financial Fact:
Interest and other income, net: 216M
Today's EPS Names:
VIVO, BIOX, PMCB, More
Join SI Premium – FREE
Amgen, Inc. (NASDAQ: AMGN) reported Q3 EPS of $1.40, $0.10 better than the analyst estimate of $1.30. Revenue for the quarter came in at $3.94 billion versus the consensus estimate of $3.87 billion.
Raised its buyback program to $10 billion.
Amgen, Inc. sees FY2011 EPS of $5.15-$5.30, versus prior guidance of $5.00-$5.20 and the consensus of $5.21. Amgen, Inc. sees FY2011 revenue of $15.4-$15.6 billion, versus prior guidance of $15.1-$15.5 billion and the consensus of $15.43 billion.
Raised its buyback program to $10 billion.
Amgen, Inc. sees FY2011 EPS of $5.15-$5.30, versus prior guidance of $5.00-$5.20 and the consensus of $5.21. Amgen, Inc. sees FY2011 revenue of $15.4-$15.6 billion, versus prior guidance of $15.1-$15.5 billion and the consensus of $15.43 billion.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- lululemon athletica (LULU) Tops Q2 EPS by $1.10, Cuts Guidance
- Amgen (AMGN) PT Raised to $435 at Wells Fargo
- Ciena (CIEN) Tops Q3 EPS by 39c, Offers Guidance
Create E-mail Alert Related Categories
Earnings, Guidance, Hot Earnings, Hot Guidance, Stock BuybacksSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
